Aileron Therapeutics effects 1-for-20 reverse stock split effective Nov 10, 2022

Rein Therapeutics, Inc.

Reverse split reduces authorized common shares from 300M to 15M, then tripled to 45M.
No fractional shares issued; stockholders get cash payment for fractional interests.
All outstanding stock options and warrants adjusted per their terms.
Split-adjusted trading begins on Nasdaq at market open on November 11, 2022.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Rein Therapeutics, Inc.: Effected a 1-for-20 reverse stock split and reduced authorized common shares from 300,000,000 to 15,000,000 then multiplied by three to 45,000,000 (effective 2022-11-10).

Change: charter amendment
Effective: 2022-11-10

Exact text from the filing

On November 10, 2022 (the “Effective Date”), Aileron Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), which effected, as of 5:00 p.m. Eastern Time on the Effective Date, a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, $0.001 par value per share (the “Common Stock”).

View on SEC.gov

Browse all governance changes →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-282637

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.